Business Context and Reporting Period
This Form 10-K was filed by Capstone Therapeutics Corp. for the fiscal year ended December 31, 2016. The filing identifies the registrant as Capstone Therapeutics Corp., not Capstone Holding Corp. The company is a biotechnology development business with no revenue-generating products. Its principal asset is a 59.3%-owned joint venture, LipimetiX Development, Inc., focused on AEM-28 and lead analog AEM-28-14 for hyperlipidemia and Homozygous Familial Hypercholesterolemia.
The company operates as a virtual organization with two administrative employees and consultants. AEM-28 Phase 1a and Phase 1b/2a trials were completed in 2014; no clinical trials were active at December 31, 2016.
Financial Metrics
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $543,000 | $1.757 million |
| Research and development expense | $1.041 million | $1.182 million |
| Interest and other expense, net | $81,000 | $24,000 |
| Consolidated net loss | $1.609 million | $2.771 million |
| Net loss attributable to Capstone stockholders | $663,000 | $2.771 million |
| Loss per share, basic and diluted | $0.02 | $0.07 |
| Cash flow used in operations | $1.209 million | $2.153 million |
| Cash and cash equivalents | $748,000 | $1.011 million |
| Convertible promissory notes payable | $1.000 million | $1.000 million |
| Accumulated deficit | $189.619 million | $188.956 million |
Total assets were $1.182 million and total liabilities were $1.304 million at December 31, 2016, resulting in stockholders’ equity of negative $122,000. Of the $748,000 in cash, $445,000 was held by the joint venture. The company’s $1 million notes bear 5% interest, are secured by substantially all company assets, and were due April 30, 2017 unless converted or otherwise addressed.
The joint venture raised $1.012 million of Series B-1 preferred stock and warrants in August 2016, generating $946,000 net proceeds. The company contributed $6 million to the joint venture and had advanced approximately $1.594 million under a revolving loan agreement at year-end.
Material Changes Versus the Prior Comparable Period
- Net loss attributable to Capstone stockholders declined to $663,000 from $2.771 million, principally because of lower operating expenses and the allocation of $946,000 of joint venture losses to Series B-1 preferred stockholders.
- G&A expense fell 69% to $543,000, reflecting salary and consulting rate reductions, lower professional fees, reduced insurance coverage, and the decision not to engage an independent public accountant.
- R&D expense decreased 12% to $1.041 million. Future development spending is expected to remain limited pending additional funding.
- Operating cash use improved to $1.209 million from $2.153 million, but cash declined by $263,000 to $748,000 after the $946,000 joint venture financing.
- Stockholders’ equity declined from positive $506,000 to negative $122,000.
- The company reduced its workforce and maintained a virtual operating model. Executive and consultant compensation was substantially reduced during 2016.
Outlook, Risks, Contingencies, and Unusual Items
Management stated that the company and joint venture do not have sufficient funding for additional material development of AEM-28-14. The company is pursuing fundraising, partnering, licensing, strategic transactions, and potential debt or equity offerings. Without additional capital, operations and development activities may be curtailed, and management disclosed substantial doubt about the company’s ability to continue as a going concern.
- The company expects no product revenue for at least several years, if ever, and expects continuing losses.
- The AEM-28-14 program remains pre-commercial and requires additional preclinical, clinical, manufacturing, and regulatory work before commercialization could occur.
- The company’s financial statements were not audited by an independent public accountant for 2016 or 2015, and the filing does not include an independent auditor’s opinion. This creates potential SEC and OTCQB compliance and trading risks.
- The $1 million convertible notes were due April 30, 2017 and could convert under specified conditions or be repaid; the filing does not state the subsequent resolution.
- The joint venture’s noncontrolling stockholders appoint a majority of its board, although Capstone owns a majority economic interest. This may limit Capstone’s operational control.
- If the joint venture cannot continue as a going concern, Capstone could recognize an additional loss of approximately $667,000 related to losses allocated to noncontrolling common interests.
- The company had no product liability coverage, was exposed to regulatory and clinical development failure, and faced substantial competition and intellectual-property risks.
- The filing reports no material legal proceedings and no material loss contingency recognized by management.
Investor Verification Priorities
- Verify the registrant identity and filing status, including the apparent discrepancy between the requested company name and the filing’s stated name.
- Review subsequent filings for repayment, conversion, or restructuring of the $1 million convertible notes due April 30, 2017.
- Confirm the company’s post-year-end cash position, financing activity, and ability to continue as a going concern.
- Assess the status, funding, and development milestones of AEM-28-14 and the joint venture.
- Review the consequences of the absence of independent audit and review procedures for SEC compliance, OTCQB eligibility, and financial statement reliability.
- Evaluate potential dilution from 3.612 million outstanding stock options and possible future debt, preferred stock, or equity financing.
- Confirm whether the company generated any subsequent revenue or entered into a partnering, licensing, merger, or other strategic transaction.